Clinical Trial Update: Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating an anti-IL5Ralpha monoclonal antibody for chronic idiopathic urticaria unresponsive to H1 antihistamines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Snippet

Sponsor: Jonathan A. Bernstein, MD | Conditions: Chronic Idiopathic Urticaria | Phase 4 | Status: COMPLETED